Skip NavigationSkip to Content
Return Return to Search Results

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

  1. Author:
    Sissung, Tristan M
    McKeeby, Jon W
    Patel, Jharana
    Lertora, Juan J
    Kumar, Parag
    Flegel, Willy A
    Adams, Sharon D
    Eckes, Ellen J
    Mickey, Frank
    Plona, Teri
    Mellott, Stephanie
    Baugher, Ryan
    Wu, Xiaolin
    Soppet, Daniel
    Barcus, Mary
    Datta, Vivekananda
    Pike, Kristen
    DiPatrizio, Gary
    Figg, William D
    Goldspiel, Barry R

  2. Author Address

    Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA., Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Pharmacy Department, NIH Clinical Center, Bethesda, MD, USA., Clinical Pharmacology Program (2006-2016), NIH Clinical Center, Bethesda, MD, USA., Clinical Pharmacokinetics Research Laboratory, NIH Clinical Center, Bethesda, MD, USA., Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA., Medical Surgical Specialties Service, Clinical Center Nursing Department, NIH, Bethesda, MD, USA., CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Genomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Molecular Characterization Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.,
    1. Year: 2017
    2. Date: Oct
  2. Journal: Journal of clinical pharmacology
    1. 57
    2. Suppl 10
    3. Pages: S67-S77
  4. Type of Article: Article
  5. ISSN: 0091-2700
  1. Abstract:

    The National Institutes of Health Clinical Center (NIH CC) is the largest hospital in the United States devoted entirely to clinical research, with a highly diverse spectrum of patients. Patient safety and clinical quality are major goals of the hospital, and therapy is often complicated by multiple cotherapies and comorbidities. To this end, we implemented a pharmacogenomics program in 2 phases. In the first phase, we implemented genotyping for HLA-A and HLA-B gene variations with clinical decision support (CDS) for abacavir, carbamazepine, and allopurinol. In the second phase, we implemented genotyping for drug-metabolizing enzymes and transporters: SLCO1B1 for CDS of simvastatin and TPMT for CDS of mercaptopurine, azathioprine, and thioguanine. The purpose of this review is to describe the implementation process, which involves clinical, laboratory, informatics, and policy decisions pertinent to the NIH CC. © 2017, The American College of Clinical Pharmacology.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/jcph.993
  3. PMID: 28921647
  4. View record in Web of Science®
  5. WOS: 000411023800006

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel